

1 **Less invasive SARS-CoV-2 testing for children: A comparison of saliva and a novel**
2 **Anterior Nasal Swab**

3

4 **Authors**

5 Shidan Tosif PhD^{1,2,3}

6 Lai-yang Lee MBBS⁴

7 Jill Nguyen BSc(Hons)²

8 Chris Selman MBioStat⁵

9 Anneke C Grobler PhD^{5,3}

10 Alissa McMinn²

11 Andrew Steer PhD^{1,2,3}

12 Andrew Daley FRACP⁴

13 Nigel Crawford PhD^{1,2,3}

14

15 **Affiliations**

16 1 Department of General Medicine, Royal Children's Hospital Melbourne

17 2 Infection and Immunity, Murdoch Children's Research Institute

18 3 Department of Paediatrics, The University of Melbourne

19 4 Department of Microbiology, The Royal Children's Hospital

20 5 Clinical Epidemiology & Biostatistics Unit, Murdoch Children's Research Institute

21

22 **Address correspondence to:** Shidan Tosif, Infection and Immunity, Murdoch Children's
23 Research Institute, 50 Flemington Rd, Parkville VIC 3052

24

25 **Words:** 1202

26

27 **Short running title:** Respiratory viral testing in children

28

29 **Conflict of Interest:** The authors have no conflicts of interest relevant to this article to
30 disclose

31

32 **Funding:** This work was supported by a grant from Rhinomed Pty Ltd and the Victorian
33 Department of Jobs, Precincts and Regions.

34

35 **Role of Funder:** The funding sources had no role in the design of this study, its execution,
36 analyses, interpretation of the data, or decision to submit results for publication.

37

38 **Clinical Trial Registration:** ClinicalTrials.gov ID NCT05043623

39

40 **Abbreviations:**

41 ANS – Anterior Nasal Swab

42 COVID-19 – Coronavirus disease 2019

43 CTN – Combined Throat and Nose Swab

44 RT-PCR - Reverse transcription polymerase chain reaction

45 SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

46

47

48

49 **Abstract**

50 Reducing procedural discomfort for children requiring respiratory testing for SARS-CoV-2 is
51 important in supporting testing strategies for case identification. Alternative sampling methods
52 to nose and throat swabs, which can be self-collected, may reduce laboratory-based testing
53 requirements and provide rapid results for clearance to attend school or hospital settings. The
54 aim of this study was to compare preference and diagnostic sensitivity of a novel anterior nasal
55 swab (ANS), and saliva, with a standard combined nose and throat (CTN) swab. The three
56 samples were self-collected by children aged 5-18 years who had COVID-19 or were a
57 household close contact. Samples were analysed by reverse transcription polymerase chain
58 reaction (RT-PCR) on the Allplex SARS-CoV-2 Assay. Most children and parents preferred
59 the ANS and saliva swab over the CTN swab for future testing. The ANS was highly sensitive
60 (sensitivity 1.000 (95% Confidence Interval (CI) 0.920, 1.000)) for SARS-CoV-2 detection,
61 compared to saliva (sensitivity 0.886, 95% CI 0.754, 0.962). We conclude the novel ANS is a
62 highly sensitive and more comfortable method for SARS-CoV-2 detection when compared to
63 CTN swab.

64

65

66

1 **Introduction**

2 Self-collection is a preferred method of respiratory sample collection for SARS-CoV-2
3 detection¹. Collecting samples in children presents challenges due to discomfort and poor
4 compliance that may impact accuracy and parental confidence in testing². Less invasive
5 samples such as saliva can be taken, however studies reflect lower sensitivity in SARS-CoV-2
6 detection compared with nasal swabs^{3,4}. Anterior nasal swabs are acceptable alternatives to
7 nasopharyngeal swabs⁵, and a novel flocked anterior nasal swab (ANS) with features to reduce
8 discomfort has been designed for children⁶. In this study, we compared self-collected
9 combined nose and throat (CTN), saliva and novel anterior nasal swabs for detection of SARS-
10 CoV-2 by polymerase chain reaction (PCR) and investigated feasibility in children aged 5-18
11 years.

12 **Methods**

13 *Study design*

14 The study was conducted at the Royal Children's Hospital Melbourne (RCH), between
15 February and May 2022. Self-collected CTN, ANS and saliva swabs were obtained
16 concurrently. Swabs were collected by the patient or assisted by the parent, without clinician
17 assistance. Swabs were collected at home, Emergency Department, or inpatient ward.
18 Informed consent was obtained prior to swab collection. Ethics approval was by The Royal
19 Children's Hospital Human Research Ethics Committee (HREC77305). This trial was
20 registered on ClinicalTrials.gov (NCT05043623).

21 *Participants*

22 Children between the ages of 5-18 years with confirmed COVID-19 in the prior 7 days, or
23 household contacts of these confirmed cases, were invited to participate.

24 *Test Methods*

25 Parents/guardians followed written instructions for collection of the samples. The CTN samples
26 were collected by swabbing the tonsillar beds and back of the throat for 3-5 seconds, followed
27 by bilateral nasal insertion and rotation 5 times against the nasal wall with a flocked swab
28 (FLOQSwab 551C, Copan, Brescia, Italy). Saliva samples were obtained by sucking a flocked
29 swab for 30 seconds (FLOQSwab 552C, Copan, Brescia, Italy). The ANS was collected by
30 inserting and leaving a Rhinoswab Junior (Rhinomed, Melbourne, Australia) in the anterior
31 nares for 60 seconds, followed by side-to-side movements for 15 seconds. The order in which
32 the swabs were taken was at the discretion of the child and parent/guardian.

33

34 *Acceptability Evaluation*

35 Acceptability was assessed by an electronic survey following the swabs. A 5-point Likert scale
36 or Wong-Baker FACES scale⁷ were used to rate comfort by the child (self-report) or parent.

37

38 *Analysis*

39 In the laboratory, each sample was eluted into 500ul of phosphate buffered saline (PBS). The
40 saliva and CTN samples were eluted through swirling. Due to the shape of the ANS, these
41 samples could not be swirled, and instead eluted through vortexing and a pulse spin. All
42 samples were extracted on Roche MagNA Pure 96 system using MagNA Pure 96 DNA and
43 Viral NA Small Volume Kit. Samples were tested on the Allplex SARS-CoV-2 Assay
44 (Seegene, Seoul, South Korea) which detects 4 target genes for SARS-CoV-2 (E, RdRP/S, N).
45 Cycle thresholds (Ct) values for E-gene were recorded, and results were reported as “detected”,
46 “not detected” or “inconclusive” in accordance with RCH laboratory standard operating
47 procedure. E-gene was chosen of the four targets based on previous research for its use as a
48 first-line target⁸.

49 *Statistical analysis*

50 Data was recorded in REDCap^{9,10} before analysis in Stata (Version 17.0)¹¹. The sensitivity of
51 ANS and saliva samples were calculated and reported with 95% confidence intervals (CIs).
52 When no virus was detected in one sample, but was present in the other, the Ct value was set at
53 the maximum number of cycles performed in the lab for the undetected sample (38.73). The
54 median difference in Ct values between the ANS and the standard CTN swab was compared. A
55 boxplot was used to compare the distribution of the Ct values using the E gene among all
56 sampling methods.

57

58 **Results**

59 53 participants were recruited and eligible for the study. One participant did not complete the
60 survey. Median age was 10.7 years (IQR 7.8-14.3) and tested 3.0 (IQR 1.0-5.0) days following
61 COVID-19 diagnosis or exposure. At time of recruitment, 43 (82.7%) were confirmed SARS-
62 CoV-2 positive and 9 were (17.3%) household contacts. 11 (20.8%) participants were
63 asymptomatic. There were 44/52 PCR SARS-CoV-2 detections from the CTN (Table 1). All
64 participants who tested positive to SARS-CoV-2 on the CTN were also detected by the ANS
65 (sensitivity 1.000 (95% CI 0.920, 1.000)). The ANS identified one additional SARS-CoV-2
66 detection not detected by CTN. Of the saliva samples, 39/44 detected SARS-CoV-2 when
67 compared to CTN (sensitivity 0.886, 95% CI 0.754, 0.962). ANS samples had a median Ct
68 value difference of -1.4 (95% CI -2.4, -0.5), compared to 7.1 (95% CI 5.6, 9.4) for saliva,
69 compared with CTN (Figure 1). Comfort scores for ANS and saliva were consistently
70 “comfortable” to “a little uncomfortable” compared with CTN scores of “more” to “really”
71 uncomfortable (see Figure 2). Amongst the three methods, saliva was the preferred sample for
72 half of children 26/51 (51.0%), the ANS 21/51 (42.9%) and CTN 0/51 (0%). Between ANS

73 and CTN for future testing, ANS was preferred by children 44/50 (88.0%) and parents 37/50
74 (74.0%).

75

76 **Discussion**

77 The novel ANS demonstrated high sensitivity with CTN for SARS-CoV-2 detection when
78 compared with saliva. The saliva and ANS had similar comfort and preference scores and were
79 both preferred over the CTN swab.

80

81 Self-collected respiratory samples for SARS-CoV-2 improve access and reduce risk of onward
82 exposure to others¹²⁻¹⁶. However, standardisation of anatomical site of collection, adequate
83 sample collection and time taken for sample delivery to the laboratory are common
84 challenges¹⁷. Additional considerations are required for children undertaking respiratory
85 testing as discomfort and procedural anxiety may impact testing success. In this study, the
86 high sensitivity of the novel ANS combined with a favourable comfort profile are strengths of
87 this method of collection. These factors are particularly important in children who may need
88 frequent testing in school or hospital settings. However, adjustment by the laboratory was
89 required for the novel ANS as it is shaped differently from the typical flocked swab and
90 therefore the technique used for sample elution deviated from routine practice.

91

92 Saliva has been described as the patient preferred sample for SARS-CoV-2 detection compared
93 with CTN, despite lower sensitivity¹⁸⁻²⁰. However, there are different methods of saliva
94 collection, including sucking on a collection device, oral swab or drooling into a container.
95 Depending on how the sample is collected, processing of the samples in the laboratory may
96 need to be adapted²¹. Collection of saliva by drool is challenging in younger children due to
97 compliance. The sucked saliva swabs used in this study were an easy sample to collect and

98 were more comfortable. This method is a feasible option for some children, such as those with
99 special needs, where other methods may not be tolerated, and a lower sensitivity threshold is
100 accepted.

101

102 Limitations of the study include adherence to written instructions was not monitored, thus there
103 may be differences in collection technique, although this reflects real life testing. The order of
104 the swabs was at the patient's discretion, and this could affect the sample quality. Further
105 research is needed to validate saliva and ANS for other respiratory viruses, and other home-
106 based testing platforms such as rapid antigen testing.

107

108 **Conclusion**

109 The novel ANS provides a more sensitive method for detection of SARS-CoV-2 in children
110 than saliva with similar comfort scores by children and parents. Further research investigating
111 methods of respiratory viral testing which reduce discomfort in children whilst providing
112 accurate diagnosis of respiratory viruses are needed.

113

114 **Acknowledgements**

115 We thank the study participants and families for their involvement in this study. We also
116 acknowledge the SAEFVIC Research Team (Hayley Giuliano, Chelsea Bartel and Anna
117 Wylie). ST is supported by a Murdoch Children's Research Institute Clinician Scientist
118 Fellowship.

119

References


1. Siegler AJ, Hall E, Luisi N, et al. Willingness to Seek Diagnostic Testing for SARS-CoV-2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations. *Open Forum Infectious Diseases*. 2020;7(7).
2. RCH National Child Health Poll. COVID-19 testing in kids: What concerns parents? Royal Children's Hospital Melbourne. Published 2020. Accessed 31st July, 2022.
3. Huber M, Schreiber PW, Scheier T, et al. High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children. *Microorganisms*. 2021;9(3):642.
4. Clifford V, Curtis N. Saliva testing for severe acute respiratory syndrome coronavirus 2 in children. *Clinical Microbiology and Infection*. 2021;27(9):1199-1201.
5. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. *PLOS ONE*. 2021;16(7):e0254559.
6. Rhinomed Pty Ltd. <https://www.rhinomed.global/about-rhino-med/sample-collection/rhinoswab-junior/>. Published 2022. Accessed 23 August, 2022.
7. Foundation W-BF. Wong-Baker FACES® Pain Rating Scale. . Published 2018. Accessed Retrieved July 2021 with permission from <http://www.WongBakerFACES.org>.
8. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):2000045.
9. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381.
10. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208.
11. StataCorp L. *Stata Statistical Software: Release 17*. Vol 17. College Station, TX: StataCorp LLC.2021.
12. Wehrhahn MC, Robson J, Brown S, et al. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. *Journal of Clinical Virology*. 2020;128:104417.
13. Altamirano J, Lopez M, Robinson IG, et al. Feasibility of Specimen Self-collection in Young Children Undergoing SARS-CoV-2 Surveillance for In-Person Learning. *JAMA Network Open*. 2022;5(2):e2148988-e2148988.
14. Kagan RM, Rogers AA, Borillo GA, Clarke NJ, Marlowe EM. Performance of Unobserved Self-Collected Nasal Swabs for Detection of SARS-CoV-2 by RT-PCR Utilizing a Remote Specimen Collection Strategy. *Open Forum Infectious Diseases*. 2021;8(4).
15. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. Reliable detection of SARS-CoV-2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular platforms. *Journal of Virological Methods*. 2021;295:114184.
16. Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. *The Lancet Infectious Diseases*. 2021;21(9):1233-1245.
17. Würstle S, Spinner CD, Voit F, et al. Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing. *Infection*. 2021;49(5):927-934.
18. Gagnon F, Bhatt M, Zemek R, Webster RJ, Johnson-Obaseki S, Harman S. Nasopharyngeal swabs vs. saliva sampling for SARS-CoV-2 detection: A cross-sectional survey of acceptability for caregivers and children after experiencing both methods. *PLOS ONE*. 2022;17(7):e0270929.
19. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Internal Medicine*. 2021;181(3):353-360.

20. Nasiri K, Dimitrova A. Comparing saliva and nasopharyngeal swab specimens in the detection of COVID-19: A systematic review and meta-analysis. *Journal of Dental Sciences*. 2021;16(3):799-805.
21. Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. *Journal of Clinical Virology*. 2020;130:104567.

Table 1: Sensitivity of sampling methods using standard CTN as the reference comparator

Sample	Result on ANS/Saliva in those detected on standard CTN		Sensitivity (95% CI)
	Detected	Not detected	
ANS	44	0	1.000 (0.920, 1.000)
Saliva	39	5	0.886 (0.754, 0.962)

Figure 1: Distribution of CT-values for E-gene among all sampling methods



^

Left: CT values detected by ANS (n=45)

Middle: CT values detected by saliva (n=39)

Right: CT values detected by standard CTN (n=44)

Figure 2 – Comfort Rating of ANS, CTN and Saliva

